These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29103760)

  • 21. Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice.
    Lendorf ME; Petersen PM; Svendsen AS; Lindberg H; Brasso K
    Eur Urol Open Sci; 2021 Feb; 24():25-33. PubMed ID: 34337492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.
    Hahn AW; Hale P; Rathi N; Agarwal N
    Curr Opin Urol; 2017 Nov; 27(6):559-565. PubMed ID: 28816716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
    Schweizer MT; Gulati R; Mostaghel EA; Nelson PS; Montgomery RB; Yu EY; Cheng HH
    Med Oncol; 2016 Jul; 33(7):77. PubMed ID: 27300548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience.
    Purshouse K; Protheroe AS
    Ther Adv Urol; 2019; 11():1756287218820804. PubMed ID: 30671143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic treatment for metastatic prostate cancer.
    Gravis G
    Asian J Urol; 2019 Apr; 6(2):162-168. PubMed ID: 31061802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM; Millett RL; Millado KF; Lin J
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
    Thomas C; Baunacke M; Erb HHH; Füssel S; Erdmann K; Putz J; Borkowetz A
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
    Ohlmann CH
    Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer.
    Shenoy N; Kohli M
    Indian J Urol; 2016; 32(4):257-261. PubMed ID: 27843206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
    Matsumura N; Fujita K; Nishimoto M; Minami T; Tahara H; Yoshimura K; Uemura H
    World J Urol; 2023 Aug; 41(8):2063-2068. PubMed ID: 36040500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Abiraterone in castration resistant prostate cancer.].
    Juárez Soto A; Caballero Cobos R; Campanario Pérez R; Saiz Marenco R; Herrera Torres M; Gamaza Martínez R; Amores Bermúdez J
    Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer.
    Jazayeri SB; Cooley LF; Srivastava A; Shore N
    Eur Urol Open Sci; 2022 Nov; 45():38-40. PubMed ID: 36186607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: Results from LATITUDE.
    Li T; Franco-Villalobos C; Proskorovsky I; Sorensen SV; Tran N; Sulur G; Chi KN
    Cancer; 2019 Feb; 125(4):626-632. PubMed ID: 30521063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upfront Chemotherapy for Metastatic Prostate Cancer.
    Lam ET; Flaig TW
    Oncology (Williston Park); 2015 Dec; 29(12):956-62. PubMed ID: 26676900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.